Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Market Outlook
Thelansis’s “Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma Overview
Epstein–Barr
virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and
elderly population and was defined as EBV-positive monoclonal large B-cell
proliferative disease. The survival of patients with EBV-positive DLBCL is
significantly worse than that of patients with EBV-negative DLBCL. Cells with
latent EBV infection express EBER protein and may express other proteins such
as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be
required for the survival of the cells in DLBCL. The immunohistochemical
profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5.
CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with
immunoblastic or plasmablastic features may lack CD20 expression. In situ
hybridization for EBER is positive and is considered the most important test in
diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor
response to treatment, so rapid detection is a necessity.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment